ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA) announced preliminary safety and efficacy data from the discontinued Phase 3 EPIC trial of Iclusig (ponatinib) vs. imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML). These data are being featured this afternoon in a poster presentation and a poster discussion session at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is 3.56%. On last trading day company shares ended up $6.69. Analysts mean target price for the company is $9.47. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average is -5.40%.
One of the world’s biggest pharmaceutical companies,Pfizer Inc. (NYSE:PFE) has witnessed an insider selling the company’s shares recently. This comes on the heels of the drug maker aborting its bid to acquire Britain-based healthcare company AstraZeneca plc (ADR) (NYSE:AZN) and its decision to settle the Neurontin drug issue for the alleged unapproved usage of the drug. The insider action also follows despite the brokerages’ consensus favoring a Buy on the stock. Pfizer Inc. (NYSE:PFE) shares fell -1.14% in last trading session and ended the day on $29.42. PFE Gross Margin is 81.90% and its return on assets is 23.50%. Pfizer Inc. (NYSE:PFE) quarterly performance is -8.46%.
Merck & Co., Inc. (NYSE:MRK)said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio. Merck & Co., Inc. (NYSE:MRK) shares moved down -0.43% in last trading session and was closed at $57.85, while trading in range of $57.68-$58.26. Merck & Co., Inc. (NYSE:MRK) year to date performance is 16.49%.
Roth Capital keeps Galena Biopharma (Nasdaq:GALE) at Buy with a price target of $7 following a recent presentation of GALE-301 Folate Binding Protein (FBP) vaccine data. Galena Biopharma Inc (NASDAQ:GALE) ended the last trading day at $2.41. Company weekly volatility is calculated as 5.79% and price to cash ratio as 5.43. Galena Biopharma Inc (NASDAQ:GALE) showed a positive weekly performance of 4.78%.
Gilead Sciences (NASDAQ:GILD) had its price target upped by Deutsche Bank from $135.00 to $142.00 in a research note issued to investors on Wednesday.Gilead Sciences, Inc. (NASDAQ:GILD) net profit margin is 33.50% and weekly performance is 1.45%. On last trading day company shares ended up $82.39. Analysts mean target price for the company is $100.57. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average is 8.07%.
Leave a Reply